ImmunityBio reports 71% complete response rate in 100-patient ANKTIVA trial; durable responses up to 54 months

ImmunityBio, Inc.

100 patients with BCG-unresponsive NMIBC CIS enrolled; 71% achieved complete response (CR) rate.
Durable response duration ranged up to 54 months in responders, supporting cystectomy avoidance.
Updated data to be submitted to EMA in Marketing Authorization Application in Q4 2024.
CR rate consistent with 71% reported for 82 patients in NEJM Evidence (Chamie 2022).
Study continues to monitor durability of responses and overall survival outcomes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.